Date: 2014-05-31
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 50th American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 to June 3, 2014, in Chicago
Company: Genentech, a member of the Roche Group (USA - Switzerland) Seattle Genetics (USA - WA)
Product: DSTP3086S
Action
mechanism: antibody drug conjugate. DSTP3086S is an antibody drug conjugate consisting of an anti-STEAP1 monoclonal antibody conjugated to the cytotoxic agent MMAE using Seattle Genetics’ ADC technology. STEAP1, a six transmembrane epithelial antigen of the prostate, is expressed in the majority of human primary and metastatic prostate tumors
Disease: metastatic prostate cancer
Therapeutic area: Cancer - Oncology
Country: USA
Trial
details: This phase I, open-label study is evaluating the safety and pharmacokinetics of escalating doses of DSTP3086S in patients with metastatic castration-resistant prostate cancer.(NCT01283373)
Latest
news: * On May 31, 2014, Seattle Genetics announced data from several collaborator antibody-drug conjugate (ADC) programs presented at the American Society of Clinical Oncology(ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. Genentech, a member of the Roche Group, is presenting data from five ADC programs, including two oral presentations. This phase I study evaluated safety and activity of DSTP3086S (0.3-2.8 mg/kg IV), an antibody-drug conjugate targeting STEAP-1 given every 3 weeks to patients with metastatic castration-resistant prostate cancer (Abstract #5024). As of 18 Dec 2013, 59 pts were enrolled with a median age of 68 (43-87), all ECOG PS 0-1, and with a median of 6 prior systemic regimens (71% received prior taxanes). DSTP3086S at dose levels between 2.25 and 2.8 mg/kg demonstrated anti-tumor activity and the RP2D is 2.4 mg/kg q3w.
